Bill 3 amends the Opioid Damages and Health Care Costs Recovery Act to bring upstream inputs and advisors into the statute’s scope. It adds “active ingredient” to the statute’s covered substances, creates a definition of “consultant” (advisors to manufacturers or wholesalers), and substitutes that term for prior references limited to manufacturers and wholesalers.
The bill also replaces the statute’s market‑share formula for manufacturers, clarifies which parties the Crown may sue to recover health‑care costs, and changes the Schedule language to list drugs or active ingredients. For public health payers and businesses in the opioid supply chain, these are materially different legal exposures and evidence burdens: more entities can be named defendants and the court’s allocation of liability is tied to new quantity measures in the amended formulas.
At a Glance
What It Does
The bill adds two defined terms—“active ingredient” and “consultant”—and replaces references to “manufacturer or wholesaler” with “manufacturer, wholesaler or consultant” throughout the Act. It repeals and substitutes the market‑share calculation for manufacturers using a specific quantity‑based formula and revises the Schedule to cover drugs or active ingredients.
Who It Affects
Pharmaceutical manufacturers, suppliers of active pharmaceutical ingredients (APIs), drug wholesalers and any advisers who provide sale or distribution advice to those firms are directly affected. The provincial Crown (the Ministry of Mental Health and Addiction and health‑care payers) gains an expanded target set for cost‑recovery actions.
Why It Matters
The changes broaden legal exposure upstream in the supply chain and create new data and litigation obligations (e.g., proving quantities sold, distributed or purchased). That alters settlement leverage, potential defendants, and the evidentiary work required in Crown recovery lawsuits for opioid‑related health costs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill starts by expanding the universe of what counts as an “opioid product.” It adds a narrow statutory definition for “active ingredient” (an active ingredient set out in the Schedule) and changes the Schedule’s wording so that the Schedule may list drugs or active ingredients. That change means raw pharmaceutical inputs, not just finished products, can be treated as opioids for the Act’s purposes if they appear in the Schedule.
Next, the bill creates a statutory definition of “consultant” that covers people who provide advisory services to wholesalers about distribution, sale or offering for sale of opioid products, and to manufacturers about the sale of active ingredients or opioid products. The Act’s prior references to liability and who the Crown can sue—previously limited to manufacturers and wholesalers—are amended to include consultants.
That makes advisory firms and certain advisers potential defendants in Crown recovery actions.On the damages mechanics, the bill replaces the existing manufacturer market‑share subsection with a new formula: mms = (mm / MM) × 100%. The statute explains the time window for the calculation (from the date of a defendant’s earliest opioid‑related wrong to the date of trial), defines mm as the quantity the manufacturer manufactured and distributed/sold/offered for sale within Alberta in that period, and defines MM as the quantity manufactured by all manufacturers that was purchased or dispensed in Alberta for providing health‑care benefits in that same period.
Those discrete quantity measures become the statutory basis for apportioning responsibility among manufacturers.Other provisions substitute “consultant” into several existing operative sections—most prominently the Crown’s direct action provision (section 2(1)) and provisions about joint breach and apportionment—so courts will consider collaboration and concerted conduct involving consultants when apportioning liability. Practically, the statute now requires courts to treat active‑ingredient suppliers and certain advisers as part of the universe of actors whose conduct can be evaluated and apportioned when the Crown seeks recovery of health‑care costs.
The Five Things You Need to Know
The bill adds two new defined terms: “active ingredient” (as set out in the Schedule) and “consultant” (advisors to wholesalers or manufacturers on sale/distribution).
The Crown’s direct action provision (section 2(1)) is amended so the Crown may sue a manufacturer, wholesaler or consultant to recover health‑care costs caused by an opioid‑related wrong.
The statute replaces the manufacturer market‑share formula with mms = (mm / MM) × 100%, and ties both numerator and denominator to specific quantity measures over the period from the defendant’s earliest wrong to trial.
Multiple provisions that previously read “manufacturer or wholesaler” or “manufacturers or wholesalers” are amended to add consultants, including the apportionment factors the court may consider in section 7(3)(e).
The Schedule’s language is revised from listing ‘a drug containing any of the following active ingredients’ to listing ‘any of the following drugs or active ingredients’, bringing upstream active ingredients explicitly into scope.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds ‘active ingredient’ and ‘consultant’ to the Act
This section inserts two new defined terms. “Active ingredient” is any active ingredient set out in the Schedule, which shifts the statute from covering only finished opioid products to potentially covering raw pharmaceutical inputs. “Consultant” is defined by function—people who advise wholesalers on distribution/sale or manufacturers on sale of active ingredients or opioid products. That functional definition is broad: it captures advisory services without requiring employment or ownership links, so commercial advisers, certain contractors, or retained consultants could be swept in as statutory actors.
Expands the manufacturer and drug definitions to include active ingredients
Multiple subclauses in the manufacturer definition and the definition of “opioid product” are edited to add active ingredients alongside opioid products and drugs. Practically, those textual inserts mean conduct involving active ingredients (manufacture, promotion, or distribution) is treated the same as conduct involving finished opioid products for purposes of establishing an opioid‑related wrong and attributing responsibility.
Replaces manufacturer market‑share formula with a quantity‑based percentage
The statute now requires courts to compute a manufacturer’s market share for a type of opioid product as mms = (mm / MM) × 100%, where mm is the manufacturer’s quantity of that product manufactured and distributed/sold/offered for sale in Alberta during the relevant time window, and MM is the quantity manufactured by all manufacturers that was purchased or dispensed in Alberta for health‑care benefits during the same window. This substitution moves the Act away from vague proportional metrics to a narrowly defined quantity accounting method, but it also creates concrete evidence and accounting demands for litigants and the court.
Adds consultants to the Crown’s targets and to apportionment analysis
The Crown’s direct action language in section 2(1) and multiple apportionment and joint‑liability provisions (including the list of conduct the court may weigh under section 7(3)(e)) are amended to add consultants where the statute previously mentioned only manufacturers or wholesalers. This expands the list of potential defendants and makes consultant conduct—such as collaboration or acting in concert—relevant to liability apportionment. For courts, that means evaluating advisory conduct alongside manufacturing and wholesaling when assigning percentages of responsibility.
Schedule wording broadened to include drugs or active ingredients
The Schedule’s introductory language is changed to permit listing either drugs or active ingredients. Because the Schedule determines which chemical compounds or finished drugs the Act treats as opioid products, this amendment is the gating mechanism: the practical scope of the new active‑ingredient regime depends on what the Schedule actually lists and how broadly it is interpreted in litigation.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- The Crown (Province of Alberta) — expands the pool of parties the Crown may sue to recover health‑care costs, increasing potential recovery sources for opioid‑related expenditures.
- Provincial health insurers and public health programs — by broadening allowable defendants and clarifying how market share is calculated, the law improves the Crown’s posture in cost‑recovery litigation and settlement negotiations that can reimburse publicly funded care.
- Alberta taxpayers and service providers — if recoveries increase, provincial budgets and health service funding burdens may be relieved indirectly, freeing resources for treatment and prevention.
Who Bears the Cost
- Manufacturers of opioid products and suppliers of active ingredients — the Act explicitly treats active ingredients as within scope and ties a manufacturer’s liability to quantity measures, increasing exposure for upstream suppliers.
- Wholesalers — the bill keeps wholesalers squarely within reach and tightens the evidentiary standard the Crown will seek to meet to prove quantities distributed or offered for sale in Alberta.
- Consultants and advisory firms — newly defined consultants who advise on sale or distribution can be named defendants and have their conduct evaluated for collaboration or concerted action, exposing advisers to litigation and reputational risk.
Key Issues
The Core Tension
The central dilemma is between maximizing public recovery of health‑care costs and imposing fair, predictable liability on commercial actors: the bill aims to broaden who can be held responsible (upstream suppliers and advisers) to secure recoveries for public health care, but that same expansion increases litigation complexity, evidentiary burdens and the risk of dragging in peripheral advisers or suppliers who had limited causal connection to opioid harms.
Two implementation problems will drive litigation. First, the amended market‑share formula depends on granular, auditable records of quantities “manufactured,” “distributed, sold or offered for sale,” and “purchased or dispensed … for the purpose of providing health care benefits.” Those terms are fact‑intensive, potentially overlapping, and will require parties and courts to resolve how to treat transfers between related entities, exports, re‑imports, contract manufacturing, and promotional discounts.
The statutory window—“from the date of the earliest opioid‑related wrong … to the date of trial”—creates a long‑running, retrospective accounting burden for many entities.
Second, the consultant definition is functional rather than narrow. It captures anyone who provides advisory services to wholesalers on distribution or to manufacturers on sale of active ingredients or opioid products.
That raises questions about who is a consultant versus a vendor or an outsourced service provider (e.g., law firms, compliance consultants, commercial brokers). The risk is over‑inclusiveness: advisers who never handled product or pricing decisions could nonetheless face discovery and indemnity exposure.
Courts will have to draw lines about the level of advisory involvement that constitutes an “opioid‑related wrong” or participation in concerted conduct.
Finally, the Schedule amendment is the statute’s switchboard. The Act’s expanded reach only matters if the Schedule lists specific active ingredients or drugs; disagreements about inclusion or the chemical scope of Schedule entries will be litigation focal points.
Those disputes will determine whether the upstream supply chain is truly in play or whether exposure remains concentrated on finished‑product manufacturers and wholesalers.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.